ArticleChinese journal of integrative medicine2026
Curzerene Induces Apoptosis in Colorectal Cancer Cells Through Inhibition of MEK/ERK Signaling Pathway.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tri- and Difluoromethylated Spiro[5.5]trienones Inhibit the Growth of Cancer Cells In Vitro and In Vivo.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the anticancer activity of curzerene in colorectal cancer (CRC) in vitro and in vivo models.
methodsHT29 and HCT8 cells were treated with different concentrations of curzerene (0, 20, 40, and 60 µg/mL) for 24 h. Cell viability was assessed using cell counting kit 8 assay, and cell proliferation was detected by colony-formation, then apoptosis rate was assessed by flow cytometry analysis. Mitochondrial membrane potential was measured using JC-1 assay kit. Intracellular calcium levels were examined using Fluo-3AM and Mag-fluo-3AM staining. Different inhibitors of cell death, including 3-methyladenine (3-MA), cloroquine (CQ), Nec-1, and carbobenzoxy-valyl-alanylaspartyl-[O-methyl]-fluoromethylketone (Z-VAD-FMK), were also utilised to validate the death mechanisms. The binding ability of curzerene to mitogen-activated extracellular signal-regulated kinase (MEK) proteins was investigated by molecular docking. In addition, the expression of key proteins such as phosphated MEK (p-MEK), phosphated extracellular regulated protein kinase (p-ERK), B-cell lymphoma-2 (Bcl-2), Bcl associated X (Bax), poly ADP-ribose polymerase (PARP) and cleaved PARP were analysed by Western blot. Finally the viable HT29 cells were injected subcutaneously into the right dorsolateral abdomen of male BALB/c nude mice for in vivo potency assessment.
resultsCurzerene inhibited proliferation and induced apoptosis in HT29 and HCT8 cells in a time- and dose-dependent manner (all P<0.05). Subsequently, we demonstrated that the apoptosis inhibitor Z-VAD-FMK (P<0.05) but not 3-MA, CQ or necrostatin-1 rescued curzerene-induced cell death. Compared with the control group, 60 µg/mL curzerene increased the expression of cleaved PARP by affecting intracellular calcium distribution, reactive oxygen species (all P<0.01), decreasing mitochondrial membrane potential and the expressions of p-MEK, p-ERK, Bcl-2, and PARP (all P<0.05), and additionally increased the expression of cleaved PARP with a molecular binding energy of -7.1 kcal/mol. The results showed that curzerene treatment inhibited the activation of MEK/ERK signaling pathway, and pretreatment with the MEK activator C16-PAF significantly alleviated curzerene-induced cell death (all P<0.05). The results of in vivo experiments showed that curzerene significantly inhibited the growth of subcutaneous transplantation tumours in hormonal nude mice.
conclusionCurzerene induces apoptosis in CRC cells through inhibition of the MEK/ERK signaling pathway, which will hopefully be a potential chemotherapeutic agent for treating CRC patients.
Indexed as
Identifiers
40053192What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.